Skip to main content
Charlene Mantia, MD, Oncology, Boston, MA

Charlene Mantia MD


Medical Oncologist at Dana-Farber Cancer Institute

Join to View Full Profile
  • 450 Brookline AveBoston, MA 02215

  • Phone+1 617-632-6328

  • Fax+1 617-632-2165

Dr. Mantia is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2017 - 2020
  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2014 - 2017
  • Albany Medical College
    Albany Medical CollegeClass of 2014

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2014 - 2026
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell Carcinoma  
    Praful Ravi, Charlene Mantia, Christopher Su, Neeraj Agarwal, Yousef Zakharia, Rana R Mckay, Vivek Narayan, Ajjai Alva, Bradley A Mcgregor, David F Mcdermott, Toni K C..., JAMA Oncology

Abstracts/Posters

  • Recurrent Intracranial Hemorrhage and Venous Thromboembolism Following Initial Intracranial Hemorrhage in Patients with Brain Tumors on Anticoagulation
    Charlene Mantia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

  • Sensitivity of treatment-free survival (TFS), a novel outcome, to subgroup analyses of patients (pts) with advanced melanoma (MEL) treated with immune checkpoint inhib... 
    2019 ASCO Annual Meeting - 6/1/2019

Authored Content

  • Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020
  • Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: